Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wj13404
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WJ13404 is an orally bioavailable, fourth-generation epidermal growth factor receptor (EGFR) inhibitor developed for the treatment of cancers with acquired EGFR mutations. It demonstrates potent inhibitory activity against EGFR mutants that are resistant to third-generation inhibitors, including Del19/T790M/C797S and L858R/T790M/C797S, while maintaining high selectivity for mutant over wild-type EGFR. The drug is being investigated primarily in non-small cell lung cancer (NSCLC) patients who have progressed after prior EGFR-targeted therapies[2][3][7].
- Other names
- WJ13404WJ-13404WJ 13404JS113JS-113JS 113WJ-004WJ004WJ 004
02
Targets
Beyond the preview
Go deeper on wj13404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wj13404.